Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials
about
Deep sea as a source of novel-anticancer drugs: update on discovery and preclinical/clinical evaluation in a systems medicine perspectiveThe 26S proteasome is a multifaceted target for anti-cancer therapiesNew molecular targets in mantle cell lymphomaAdvances in the understanding of mechanisms and therapeutic use of bortezomibLessons from the past and charting the future of marine natural products drug discovery and chemical biologyNew investigational drugs with single-agent activity in multiple myelomaMechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone RemodelingTrial Watch: Proteasomal inhibitors for anticancer therapyPathophysiological processes in multiple sclerosis: focus on nuclear factor erythroid-2-related factor 2 and emerging pathwaysDeubiquitinases (DUBs) and DUB inhibitors: a patent reviewProteasome inhibitors in glioblastomaNatural products from mangrove actinomycetes.Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonismBioactive natural products from Papua New Guinea marine sponges.The marine actinomycete genus Salinispora: a model organism for secondary metabolite discoveryOverview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Molecular targeted approaches in mantle cell lymphoma.Diversity and biotechnological potential of microorganisms associated with marine sponges.Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.Selective overproduction of the proteasome inhibitor salinosporamide A via precursor pathway regulation.Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedsideA strategy for dual inhibition of the proteasome and fatty acid synthase with belactosin C-orlistat hybrids.Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivoDrug discovery from marine microbes.E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis.Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells.Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence.Targeting ubiquitination for cancer therapies.Inhibitors of the immunoproteasome: current status and future directionsRemodeling natural products: chemistry and serine hydrolase activity of a rocaglate-derived β-lactone.Clinical and investigational use of proteasome inhibitors for transplant rejection.Exploiting nature's rich source of proteasome inhibitors as starting points in drug development.Proteasome inhibitors: an expanding army attacking a unique target.Proteasome inhibitors in multiple myeloma: 10 years later.Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.New proteasome inhibitors in myeloma.Deregulated chromatin remodeling in the pathobiology of brain tumors.Small molecules as pro-apoptotic anticancer agents.Peptide-based proteasome inhibitors in anticancer drug design.
P2860
Q26776294-C79207AE-DCC9-45DD-AB32-F71443D007D4Q26795764-B40AE9D1-3BDD-44A8-A09F-2C25C4AE9E2BQ26821766-B985A035-2FC4-4519-A8A2-EFAA8B966693Q26849940-CDE0C653-BFA0-4A60-AE8A-01EDC745D39FQ26863108-CF31B4AB-061C-4E5B-92DD-55A96899AB92Q28071551-7265783E-006E-4EF8-B4D8-271A2CA083AEQ28082335-FC362B9E-79F6-4012-A375-44446237E69AQ28082910-8B6C10AB-D02A-4BE0-9448-88FBBC0F5086Q28235168-8316CB07-1323-4398-A1BD-BB6FADD9EF70Q28834608-AD14F489-0B93-4306-994E-E21E9C73AA45Q33598931-637D2BB7-3861-47DC-B4F7-EF6736867515Q33736692-4B3CC4D0-0036-470D-AA7A-F565319E22B8Q34079481-9555A6A8-1B11-4C12-9922-B85695673035Q34451799-0304CAB6-2E2F-4526-8EFE-3BD717FBF868Q34465208-8906AF3E-8822-4A41-8F21-44FC331D299DQ34788381-9D51D633-9CCF-4884-84A8-F32B353C36B9Q35127368-F75A5C9C-3ABB-4270-8D29-87449ED660E7Q35203338-3F28DEA4-B3C9-425C-9342-6E207A2FE013Q35572018-73E88F64-90E4-4ED1-8C9E-8F33984D9448Q35634544-1136C72B-27F0-42A2-B387-EBD4ADF2AC55Q35989980-C5C503CF-B225-4D2F-918F-1F6BF854F1F5Q36290627-3D54632B-31A8-464E-B5A7-E971F3E2C110Q36470302-A5499737-457C-4C27-8531-231DDC1E695BQ36500531-0B4ACB43-F6F7-4B3A-A060-092F358427D9Q36807743-31D7E7B7-62D8-4ED1-BC95-1A9DF0E464DEQ37006778-8B4C6AFB-FF32-456D-AD7D-5175069FCFDEQ37015742-B5203D52-4B08-45A8-9B4D-C5A586F10EB9Q37146294-B0064B6F-D080-4E87-A369-11DFF745BB05Q37158445-A5E6F296-1CB8-42BD-8722-EB34504460D5Q37292307-BE9ECF1B-ED56-4868-A1C2-5F21BE1394CBQ37689578-2E059F4D-CA47-4BBC-B6DF-AD52A48FC8BFQ37931981-58D1B589-5CD2-41B0-B1AD-C980F3A2816CQ37951013-775D79C9-BA37-4D43-B007-5827FC1BEC69Q37979388-D32D460E-FD29-4E29-A1DA-836467BF65F5Q38014395-F792D370-01E7-4E19-8CF0-F1DA8A7A9204Q38019864-42E30A5F-C453-4635-B240-160948C667CCQ38052079-8A179E8B-30B6-4A61-BEC3-BBF38029E46CQ38056842-52B01AC4-2337-4798-8B65-873BC6FD4146Q38162939-3BC7DC4B-0F75-4F31-9A7B-AF7381F08DF1Q38192572-4A52EC07-6C1D-40DB-9EC4-3A65AF4E615D
P2860
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Marizomib, a proteasome inhibi ...... framework for clinical trials
@en
Marizomib, a proteasome inhibi ...... framework for clinical trials.
@nl
type
label
Marizomib, a proteasome inhibi ...... framework for clinical trials
@en
Marizomib, a proteasome inhibi ...... framework for clinical trials.
@nl
prefLabel
Marizomib, a proteasome inhibi ...... framework for clinical trials
@en
Marizomib, a proteasome inhibi ...... framework for clinical trials.
@nl
P2093
P2860
P1476
Marizomib, a proteasome inhibi ...... framework for clinical trials
@en
P2093
A M Roccaro
B Bonavida
C P Miller
D J McConkey
P2860
P304
P356
10.2174/156800911794519716
P577
2011-03-01T00:00:00Z